Barclays raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps an Overweight rating on the shares. The firm says the company’s ignition business is inflecting, and the guidance raise on Shield and Oncology give it confidence “that things are just getting started.” Barclays believes the stock can “continue its run.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Reports Strong Q1 2025 Growth
- Guardant Health reports Q1 EPS (49c), consensus (59c)
- Guardant Health raises FY25 revenue view to $880M-$890M from $850M-$860M
- Guardant Health’s Shield Test Shows Promise in MCED Market Despite Challenges
- Guardant Health, Pfizer team to develop and commercialize new cancer therapies